BGB-16673 is able to degrade both wild-type (WT) BTK as well as BTK with known mutations causing resistance to covalent and non-covalent BTKis, and in pre-clinical models demonstrated tumor suppression [49]. The gene discussed is BTK; the disease is neoplasm.